Blaze Bioscience Inc.
8
0
0
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
25.0%
2 terminated/withdrawn out of 8 trials
71.4%
-15.1% vs industry average
0%
0 trials in Phase 3/4
40%
2 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System
Role: collaborator
A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery
Role: collaborator
Expanded Access for BLZ-100 (Tozuleristide)
Role: lead
Study of Tozuleristide and the Canvas Imaging System in Pediatric Subjects With CNS Tumors Undergoing Surgery
Role: lead
Study of BLZ-100 in Pediatric Subjects With CNS Tumors
Role: lead
Exploratory Study of Safety and ex Vivo Fluorescence of BLZ-100 in Adult Subjects With Solid Tumors Undergoing Surgery
Role: lead
Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery
Role: lead
Safety Study of BLZ-100 in Adult Subjects With Glioma Undergoing Surgery
Role: lead
All 8 trials loaded